Table 2. Prevalences of metabolic comorbidities in early onset patients currently aged 18–39 years, early onset patients currently aged over 40 years and late onset patients.

	EOPa	LOPa	P-value
NAFLD
18-39yrs, (%)	85.3		<0.05b,c
> = 40yrs, (%)	65.4	40.4
Hypertriglyceridemia
18-39yrs, (%)	43.4		<0.05b,c
> = 40yrs, (%)	41.5	25.7
Diabetes
18-39yrs, (%)	8.5		<0.05b,c
> = 40yrs, (%)	9.2	31.7
Hyperuricemia
18-39yrs, (%)	22.5		<0.05b,c
> = 40yrs, (%)	16,9	2.7
Metabolic syndrome
18-39yrs, (%)	18.6		NSb<0.05c
> = 40yrs, (%)	22.3	14.2

NAFLD, nonalcoholic fatty liver disease.

a: early onset psoriasis (EOP), late onset psoriasis (LOP).

b: significance level between early onset patients currently aged 18–39 years and late onset patients.

c: significance level between early onset patients currently aged over 40 years and late onset patients.